LeMaitre Vascular, Inc.
$73.61-$1.25 (-1.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $2.1B
- P/E
- 37.0x
- EV / EBITDA
- 25.3x
- Revenue
- $249.6M
- Net margin
- 23.1%
- ROCE
- 11.7%
Price chart
Technical chartScreen technicals →-12.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -11.7%
- 3M
- -10.6%
- 6M
- -27.4%
- 1Y
- -12.8%
- 5Y
- +41.9%
52-week range
Day change -$1.25 (-1.7%) from $75 to $74 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in LMAT, bought on each weekday since 2021.
News & filings
What LeMaitre Vascular filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe P/E of 37.0 is more than four times the peer median of 4.7.
Strengths (1)
- Current assets are more than ten times current liabilities.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Read moreShow less
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 22.6M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $2.1B
- P/E
- 37.0x
- P/B
- 5.4x
- EV / EBITDA
- 25.3x
- EV / Sales
- 9.2x
- P/S
- 8.6x
- 52-week high
- $117.39
- 52-week low
- $73.61
Profitability
- Operating margin
- 27.2%
- Net margin
- 23.1%
- EBITDA margin
- 36.4%
- ROE
- 14.7%
- ROCE
- 11.7%
- ROA
- 9.4%
- Asset turnover
- 0.41
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $249.6M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 13.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 15.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 31.1%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $74.5M
Solvency
- Current ratio
- 12.89
- Debt / Equity
- 0.47
- Debt / Assets
- 0.30
- CFO / Net profit
- 1.41
- Cash / Market cap
- 1.3%
Where the revenue went
Of every $100 of FY2025 revenue, $23 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $71.1M |
| Revenue | Gross profit | $178.5M |
| Gross profit | Research and development | $14.1M |
| Gross profit | Selling, general and administrative | $96.5M |
| Gross profit | Operating income | $67.9M |
| Operating income | Pretax income | $67.9M |
| Interest and other income | Pretax income | $7.3M |
| Pretax income | Tax and other | $17.5M |
| Pretax income | Net income | $57.7M |
Revenue and net profit
Revenue grew 13.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $161.7M | $20.6M |
| FY2023 | $193.5M | $30.1M |
| FY2024 | $219.9M | $44.0M |
| FY2025 | $249.6M | $57.7M |
Cash flows
FY2025: $81.3M from operations, $74.5M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $25.4M | $22.1M |
| FY2023 | $36.8M | $29.5M |
| FY2024 | $44.1M | $37.2M |
| FY2025 | $81.3M | $74.5M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $249.6M+13.5%1Y
- EBITDA
- $90.8M+36.1%1Y
- Net profit
- $57.7M+31.1%1Y
- Cash from operations
- $81.3M+84.1%1Y
- Free cash flow
- $74.5M+100.4%1Y
- Revenue CAGR, 3Y
- 15.6%
- Net profit CAGR, 3Y
- 40.9%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $249.6M | $90.8M | $57.7M | $74.5M | 14.7% | +13.5% | +31.1% |
Monthly returns
Month-by-month returns of LMAT across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $615.7M |
| Current assets | $468.2M |
| Non-current assets | $147.5M |
| Liabilities | $222.2M |
| Current liabilities | $36.3M |
| Non-current liabilities | $185.8M |
| Equity | $393.5M |
| Paid-in capital | $228.4M |
| Retained earnings | $184.7M |
| Treasury stock | $17.4M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; LMAT highlighted.
P/E against peers
LMAT trades at 37.0x earnings against a peer median of 4.7x (a 680% premium).
Not shown (no positive earnings and no EV / Sales): Supernus Pharmaceuticals, Inc., Acadia Healthcare Company, Inc., Neogen Corporation, Sarepta Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| LeMaitre Vascular, Inc.LMATthis companyP/E ↑ premium | $2.1B | 37.0x | 5.4x | 14.7% | 25.3x |
| Supernus Pharmaceuticals, Inc.SUPN | $2.6B | -67.3x | 2.4x | -3.6% | 58.9x |
| TransMedics Group, Inc.TMDX | $2.5B | 13.0x | 5.2x | 40.2% | 16.8x |
| Acadia Healthcare Company, Inc.ACHC | $2.3B | -2.1x | 1.2x | -56.6% | -6.5x |
| Prestige Consumer Healthcare Inc.PBH | $2.2B | 11.3x | 1.1x | 10.1% | 9.5x |
| Select Medical Holdings CorporationSEM | $2.0B | 14.0x | 1.2x | 8.6% | 9.2x |
| Neogen CorporationNEOG | $2.0B | -1.8x | 1.0x | -52.7% | -2.9x |
| ADMA Biologics, Inc.ADMA | $1.8B | 12.6x | 3.9x | 30.8% | 9.3x |
| Sarepta Therapeutics, Inc.SRPT | $1.8B | -2.5x | 1.5x | -62.5% | -3.2x |
| Peer median | — | 4.7x | 1.4x | 2.5% | 9.3x |
Year-to-date ROI
LMAT since 1 January, against earlier years.
Historical volatility
LMAT's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 18.5% |
| FY2023 | 19.2% |
| FY2024 | 23.8% |
| FY2025 | 27.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $249.6M |
| Cost of revenueCost Of Revenue | $71.1M |
| Gross profitGross Profit | $178.5M |
| Operating expensesOperating Expense | $110.6M |
| Research and developmentResearch And Development | $14.1M |
| Selling, general and administrativeSelling General And Administration | $96.5M |
| Total expensesTotal Expenses | $181.7M |
| Operating incomeOperating Income | $67.9M |
| Interest and other | |
| Pretax incomePretax Income | $75.2M |
| TaxTax Provision | $17.4M |
| Net incomeNet Income | $57.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $615.7M |
| Current assetsCurrent Assets | $468.2M |
| Non-current assetsTotal Non Current Assets | $147.5M |
| LiabilitiesTotal Liabilities Net Minority Interest | $222.2M |
| Current liabilitiesCurrent Liabilities | $36.3M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $185.8M |
| EquityTotal Equity Gross Minority Interest | $393.5M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $81.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $81.3M |
| Net income, continuing operationsNet Income From Continuing Operations | $57.7M |
| Depreciation and amortisationDepreciation And Amortization | $10.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $10.4M |
| Stock-based compensationStock Based Compensation | $7.8M |
| Deferred taxDeferred Tax | $2.3M |
| Deferred income taxDeferred Income Tax | $2.3M |
| Operating gains and lossesOperating Gains Losses | -$180.0k |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Gain loss on sale of businessGain Loss On Sale Of Business | $0.00 |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | $540.0k |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | -$180.0k |
| Asset impairmentAsset Impairment Charge | $2.7M |
| Provision and write off of assetsProvisionand Write Offof Assets | $820.0k |
| Change in working capitalChange In Working Capital | -$1.8M |
| Other non-cash itemsOther Non Cash Items | $870.0k |
| Investing cash flowInvesting Cash Flow | -$64.9M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$64.9M |
| Capital expenditureCapital Expenditure | -$6.8M |
| Purchase of PP&EPurchase Of PPE | -$6.8M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$6.8M |
| AcquisitionsPurchase Of Business | -$1.9M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$1.9M |
| Purchase of investmentsPurchase Of Investment | -$641.3M |
| Sale of investmentsSale Of Investment | $585.1M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$56.3M |
| Financing cash flowFinancing Cash Flow | -$14.5M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$14.5M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | $0.00 |
| Short-term debt issuedShort Term Debt Issuance | — |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | — |
| Net long-term debt issuedNet Long Term Debt Issuance | $0.00 |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | — |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | $5.0M |
| Dividends paidCash Dividends Paid | -$18.1M |
| Common dividends paidCommon Stock Dividend Paid | -$18.1M |
| Other financing chargesNet Other Financing Charges | -$1.4M |
| Change in cashChanges In Cash | $1.8M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 86.0% |
| Cash at the start of the yearBeginning Cash Position | $25.6M |
| Cash at the end of the yearEnd Cash Position | $28.2M |
| Free cash flowFree Cash Flow | $74.5M |
| Supplemental |
Learn while you research
Academy chapters picked for LeMaitre Vascular, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 37.0, learn when high multiples are justified.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read